More on CGEM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $14.92 |
|
|||
| Open | $14.95 | ||||
| 52 Wk High | $0.19 | ||||
| 52 Wk Low | $0.03 | ||||
| Day High | $14.95 | ||||
| Day Low | $13.86 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 485,204 | ||||
- Zipalertinib shows 30% intracranial response rate in lung cancer trial
- Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases
- Cullinan Therapeutics doses first patient in phase 2 AML study
- Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
- H.C. Wainwright Reiterates Buy Rating on Cullinan Oncology Inc. (CGEM)
- Form 8-K Cullinan Therapeutics, For: Oct 01
- Cullinan files NDA for zipalertinib combo in first-line lung cancer
- New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
- Cullinan Therapeutics plans Q4 2026 data readouts for three pipeline drugs
- Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Entities mentioned with CGEM
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
